2021 Q4 Year-end report

• Revenues for the quarter amounted to SEK 21.0 million (8.9). Total revenues up to and including the fourth quarter amounted to SEK 81.8 million (29.3), which is growth of 179% for the entire year.
• Operating result was SEK -25.7 million (-12.3). Total operating result was SEK -78.0 million up to and including the fourth quarter (-43.1).
• The Group's result after financial items was SEK -26.5 million (-12.5).
• Earnings per share attributable to the shareholders of the Parent Company totaled SEK -0.44 (-0.21).
• Equity on the balance sheet date was SEK 142.6 million (201.9) or SEK 1.89 per share (3.43).
• Debt/equity ratio was 60% (83%) on the balance sheet date.
• Cash flows from operating activities amounted to SEK -31.5 million (-22.3).
• On the balance sheet date, the Group's cash and cash equivalents totaled SEK 28.6 million (151.9).

Significant events in the period

• November 29, 2021 | The Board of Directors of Cell Impact has resolved on a fully guaranteed rights issue of up to approximately SEK 349 million
• December 27, 2021 | Cell Impact announces final outcome of fully guaranteed rights issue